TherapeuticsMD Inc (NYSEMKT:TXMD)‘s stock had its “buy” rating reaffirmed by investment analysts at Oppenheimer Holdings Inc. in a research note issued on Wednesday.

TXMD has been the subject of several other reports. Goldman Sachs Group Inc reissued a “buy” rating and set a $10.50 target price on shares of TherapeuticsMD in a research report on Sunday, December 4th. Jefferies Group LLC restated a “positive” rating and set a $18.00 price target on shares of TherapeuticsMD in a report on Wednesday, January 25th. Cantor Fitzgerald started coverage on shares of TherapeuticsMD in a report on Friday, December 16th. They set an “overweight” rating on the stock. Finally, Zacks Investment Research cut shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a research note on Thursday, January 5th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. TherapeuticsMD has an average rating of “Buy” and a consensus target price of $20.71.

Analyst Recommendations for TherapeuticsMD (NYSEMKT:TXMD)

TherapeuticsMD (NYSEMKT:TXMD) opened at 4.91 on Wednesday. TherapeuticsMD has a one year low of $4.39 and a one year high of $9.29. The company’s 50-day moving average price is $6.61 and its 200-day moving average price is $6.20. The firm’s market cap is $969.84 million.

TherapeuticsMD (NYSEMKT:TXMD) last posted its quarterly earnings results on Thursday, February 23rd. The specialty pharmaceutical company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). The company earned $4.49 million during the quarter, compared to the consensus estimate of $5.91 million. During the same period last year, the firm posted ($0.10) earnings per share. The company’s revenue for the quarter was down 20.2% on a year-over-year basis. On average, analysts anticipate that TherapeuticsMD will post ($0.45) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Marea Informative and is the property of of Marea Informative. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at http://www.mareainformativa.com/therapeuticsmd-inc-txmd-clasificacion-reiterado-por-oppenheimer-holdings-inc/108224/.

A number of hedge funds have recently bought and sold shares of TXMD. WFG Advisors LP bought a new position in shares of TherapeuticsMD during the fourth quarter worth approximately $204,000. Greenwood Capital Associates LLC bought a new position in shares of TherapeuticsMD during the fourth quarter worth approximately $100,000. Managed Account Services Inc. bought a new position in shares of TherapeuticsMD during the fourth quarter worth approximately $104,000. Raymond James Financial Services Advisors Inc. bought a new position in shares of TherapeuticsMD during the fourth quarter worth approximately $106,000. Finally, Traynor Capital Management Inc. raised its position in shares of TherapeuticsMD by 21.2% in the third quarter. Traynor Capital Management Inc. now owns 20,000 shares of the specialty pharmaceutical company’s stock worth $119,000 after buying an additional 3,500 shares during the last quarter.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Receive News & Stock Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related stocks with our FREE daily email newsletter.